Individualised treatment of COPD exacerbations using biomarkers

Pradeesh Sivapalan; Josefin Eklöf; Barbara Bonnesen; Louise Tønnesen; Torgny Wilcke; Jens-Ulrik Stæhr Jensen

doi:10.61409/V09230560

Individualised treatment of COPD exacerbations using biomarkers

Pradeesh Sivapalan, Josefin Eklöf, Barbara Bonnesen, Louise Tønnesen, Torgny Wilcke, Jens-Ulrik Stæhr Jensen

Abstract

This review highlights key aspects of treating chronic obstructive pulmonary disease (COPD) exacerbation, focusing on the optimisation of systemic corticosteroid and antibiotic use through personalised treatment using biomarkers. Eosinophil-guided therapy reduces corticosteroid usage which might reduce side effects, while procalcitonin-guided therapy contributes to reduced antibiotic consumption. These approaches, documented through well-conducted randomized controlled trials, suggest the possibility of enhancing COPD exacerbation management, reducing potential side effects, and addressing concerns related to antibiotic resistance.

Bidragets oversatte titel	Not Available
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	14
Antal sider	7
ISSN	0041-5782
DOI	https://doi.org/10.61409/V09230560
Status	Udgivet - 1 apr. 2024

Emneord

Humans
Adrenal Cortex Hormones/therapeutic use
Anti-Bacterial Agents/therapeutic use
Biomarkers
Disease Progression
Glucocorticoids/therapeutic use
Pulmonary Disease, Chronic Obstructive/drug therapy
Randomized Controlled Trials as Topic

Adgang til dokumentet

10.61409/V09230560

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{e95d8499badf435c9a817e41b4e678e6,

title = "Individualised treatment of COPD exacerbations using biomarkers",

abstract = "This review highlights key aspects of treating chronic obstructive pulmonary disease (COPD) exacerbation, focusing on the optimisation of systemic corticosteroid and antibiotic use through personalised treatment using biomarkers. Eosinophil-guided therapy reduces corticosteroid usage which might reduce side effects, while procalcitonin-guided therapy contributes to reduced antibiotic consumption. These approaches, documented through well-conducted randomized controlled trials, suggest the possibility of enhancing COPD exacerbation management, reducing potential side effects, and addressing concerns related to antibiotic resistance.",

keywords = "Humans, Adrenal Cortex Hormones/therapeutic use, Anti-Bacterial Agents/therapeutic use, Biomarkers, Disease Progression, Glucocorticoids/therapeutic use, Pulmonary Disease, Chronic Obstructive/drug therapy, Randomized Controlled Trials as Topic",

author = "Pradeesh Sivapalan and Josefin Ekl{\"o}f and Barbara Bonnesen and Louise T{\o}nnesen and Torgny Wilcke and Jensen, {Jens-Ulrik St{\ae}hr}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = apr,

day = "1",

doi = "10.61409/V09230560",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "14",

}

TY - JOUR

T1 - Individualised treatment of COPD exacerbations using biomarkers

AU - Sivapalan, Pradeesh

AU - Eklöf, Josefin

AU - Bonnesen, Barbara

AU - Tønnesen, Louise

AU - Wilcke, Torgny

AU - Jensen, Jens-Ulrik Stæhr

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/4/1

Y1 - 2024/4/1

N2 - This review highlights key aspects of treating chronic obstructive pulmonary disease (COPD) exacerbation, focusing on the optimisation of systemic corticosteroid and antibiotic use through personalised treatment using biomarkers. Eosinophil-guided therapy reduces corticosteroid usage which might reduce side effects, while procalcitonin-guided therapy contributes to reduced antibiotic consumption. These approaches, documented through well-conducted randomized controlled trials, suggest the possibility of enhancing COPD exacerbation management, reducing potential side effects, and addressing concerns related to antibiotic resistance.

AB - This review highlights key aspects of treating chronic obstructive pulmonary disease (COPD) exacerbation, focusing on the optimisation of systemic corticosteroid and antibiotic use through personalised treatment using biomarkers. Eosinophil-guided therapy reduces corticosteroid usage which might reduce side effects, while procalcitonin-guided therapy contributes to reduced antibiotic consumption. These approaches, documented through well-conducted randomized controlled trials, suggest the possibility of enhancing COPD exacerbation management, reducing potential side effects, and addressing concerns related to antibiotic resistance.

KW - Humans

KW - Adrenal Cortex Hormones/therapeutic use

KW - Anti-Bacterial Agents/therapeutic use

KW - Biomarkers

KW - Disease Progression

KW - Glucocorticoids/therapeutic use

KW - Pulmonary Disease, Chronic Obstructive/drug therapy

KW - Randomized Controlled Trials as Topic

UR - http://www.scopus.com/inward/record.url?scp=85190486448&partnerID=8YFLogxK

U2 - 10.61409/V09230560

DO - 10.61409/V09230560

M3 - Review

C2 - 38606705

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 14

ER -

Individualised treatment of COPD exacerbations using biomarkers

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater